Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China.
School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
OMICS. 2019 Dec;23(12):649-659. doi: 10.1089/omi.2019.0099. Epub 2019 Jul 16.
Cardiovascular disease is a common complex trait that calls for next-generation biomarkers for precision diagnostics and therapeutics. The most common type of post-translational protein modification involves glycosylation. Glycans participate in key intercellular and intracellular functions, such as protein quality control, cell adhesion, cell-cell recognition, signal transduction, cell proliferation, and cell differentiation. In this context, immunoglobulin G (IgG) -glycans affect the anti-inflammatory and proinflammatory responses of IgG, and are associated with cardiometabolic risk factors such as aging, central obesity, dyslipidemia, and hyperglycemia. Yet, the role of such glycomic biomarkers requires evaluation in diverse world populations. We report here original observations on association of IgG -glycan biosignatures with 15 cardiometabolic risk factors in a community-based cross-sectional study conducted in 701 Chinese Han participants. After controlling for age and sex, we found that the 16, 21, and 18 IgG -glycan traits were significantly different in participants with and without metabolic syndrome, hypertriglyceridemic waist phenotype, or abdominal obesity, respectively. The canonical correlation analysis showed that IgG -glycan profiles were significantly associated with cardiometabolic risk factors ( = 0.469, < 0.001). Classification models based on IgG -glycan traits were able to differentiate participants with (1) metabolic syndrome, (2) hypertriglyceridemic waist phenotype, or (3) abdominal obesity from controls, with an area under receiver operating characteristic curves (AUC) of 0.632 (95% confidence interval [CI], 0.574-0.691, < 0.001), 0.659 (95% CI, 0.587-0.730, < 0.001), and 0.610 (95% CI, 0.565-0.656, < 0.001), respectively. These new data suggest that IgG -glycans may play an important role in cardiometabolic disease pathogenesis by regulating the proinflammatory or anti-inflammatory responses of IgG. Looking into the future, IgG -glycan biosignatures warrant further research in other world population samples with a view to applications in clinical cardiology and public health practice.
心血管疾病是一种常见的复杂特征，需要新一代的生物标志物来进行精准诊断和治疗。最常见的翻译后蛋白质修饰类型涉及糖基化。聚糖参与关键的细胞内和细胞间功能，如蛋白质质量控制、细胞黏附、细胞-细胞识别、信号转导、细胞增殖和细胞分化。在这种情况下，免疫球蛋白 G（IgG）-聚糖会影响 IgG 的抗炎和促炎反应，并与心血管代谢危险因素相关，如衰老、中心性肥胖、血脂异常和高血糖。然而，这种糖组生物标志物的作用需要在不同的世界人群中进行评估。我们在此报告了在一项在中国汉族参与者中进行的基于社区的横断面研究中，关于 IgG-聚糖生物标志物与 15 种心血管代谢危险因素之间关联的原始观察结果。在控制年龄和性别后，我们发现，在患有和不患有代谢综合征、高甘油三酯血症性腰围表型或腹部肥胖的参与者中，16、21 和 18 种 IgG-聚糖特征分别存在显著差异。典型相关分析显示，IgG-聚糖谱与心血管代谢危险因素显著相关（ = 0.469， < 0.001）。基于 IgG-聚糖特征的分类模型能够区分患有（1）代谢综合征、（2）高甘油三酯血症性腰围表型或（3）腹部肥胖的参与者和对照组，其受试者工作特征曲线（ROC）下面积分别为 0.632（95%置信区间 [CI]，0.574-0.691， < 0.001）、0.659（95% CI，0.587-0.730， < 0.001）和 0.610（95% CI，0.565-0.656， < 0.001）。这些新数据表明，IgG-聚糖可能通过调节 IgG 的抗炎或促炎反应，在心血管代谢疾病发病机制中发挥重要作用。展望未来，IgG-聚糖生物标志物需要在其他世界人群样本中进一步研究，以期在临床心脏病学和公共卫生实践中得到应用。
